Prior Auth

Prior Authorization for Cancer Drugs: Oncology PA Guide 2026

How oncology prior authorization works in 2026 — NCCN criteria, biomarker requirements, checkpoint inhibitor PA, CAR-T approval pathways, and appeal strategies for cancer drug denials.

RxCheckUp Clinical Team · 2026-05-11 · 14 min read

Why Oncology Prior Authorization Is Different

Prior authorization for cancer drugs operates under a fundamentally different framework than PA for other specialty drugs. Most commercial payers and Medicare Advantage plans anchor oncology PA decisions to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines — a set of consensus-based, regularly updated treatment recommendations that stratify interventions by Category (1: high-level evidence, uniform consensus; 2A: lower-level evidence, uniform consensus; 2B: lower-level evidence, consensus; 3: any level of evidence, major disagreement). Payers typically cover NCCN Category 1 and 2A recommendations without requiring an off-label justification, even when the drug is prescribed outside its FDA-labeled indication.

This means that for oncology, the key clinical leverage point is demonstrating that the regimen falls within an NCCN guideline recommendation for the patient's tumor type, stage, histology, and biomarker profile — not simply that the drug is FDA-approved. FDA approval for one tumor type does not automatically translate to payer coverage for a different tumor type, even when NCCN includes that use. And conversely, an off-label use that has no FDA approval but is included in NCCN as a Category 1 recommendation is generally coverable and should be submitted as such.

The NCCN Framework for Oncology PA

NCCN Clinical Practice Guidelines are organized by tumor type (e.g., Non-Small Cell Lung Cancer, Breast Cancer, Diffuse Large B-Cell Lymphoma). Each guideline provides algorithm-driven treatment recommendations stratified by disease stage, biomarker profile, performance status, and line of therapy. For payer purposes, the most critical elements are:

✓ Category of recommendation (1, 2A, 2B, 3) — most payers cover 1 and 2A; 2B and 3 require off-label justification
✓ Biomarker designation — many NCCN recommendations are biomarker-contingent (e.g., pembrolizumab as first-line NSCLC only when PD-L1 TPS ≥50%; osimertinib for EGFR-mutant NSCLC)
✓ Line of therapy — NCCN specifies whether a recommendation applies in the first-line, second-line, or subsequent settings; payers check line of therapy against prior treatment documentation
✓ Tumor histology — NCCN recommendations often differ by histologic subtype (squamous vs. non-squamous, luminal A vs. HER2+ breast, etc.)
✓ Performance status — some recommendations are restricted to ECOG 0-1 or 0-2; patients with poor PS may fall outside the covered criterion

Biomarker Documentation: The Most Common Cause of Oncology PA Denials

Biomarker requirements have become the primary source of oncology PA denials. As precision oncology has expanded, payers have built biomarker testing requirements directly into their coverage criteria. Missing or ambiguous biomarker documentation is now the single most frequently cited basis for initial oncology PA denials.

For checkpoint inhibitor monotherapy (pembrolizumab, nivolumab, atezolizumab, durvalumab, cemiplimab), the key biomarkers are PD-L1 expression (by IHC, reported as TPS or CPS), tumor mutational burden (TMB-H, defined as ≥10 mutations per megabase by FDA-approved assay), and microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR). Each drug and indication has a specific biomarker threshold — pembrolizumab NSCLC monotherapy requires PD-L1 TPS ≥50%; for gastric and GEJ adenocarcinoma combination therapy, the threshold is CPS ≥1. Mixing these thresholds across indications is a frequent documentation error.

For targeted therapies, biomarker requirements are even more explicit: EGFR-mutant (osimertinib, erlotinib, afatinib), ALK-rearranged (alectinib, brigatinib, lorlatinib), KRAS G12C (sotorasib, adagrasib), HER2-overexpressing or HER2-mutant (trastuzumab, pertuzumab, ado-trastuzumab emtansine, fam-trastuzumab deruxtecan), BRCA1/2-mutated (olaparib, niraparib, rucaparib), and BRAF V600E (vemurafenib, dabrafenib/trametinib, encorafenib). The biomarker must be documented with the test name, result, laboratory, and testing methodology.

What Documentation Must Accompany an Oncology PA

A complete oncology PA submission reduces first-pass denials by 60-70% compared to incomplete submissions. Required documentation for most oncology PA requests:

✓ Pathology report confirming tumor type, histology, and stage with AJCC staging criteria
✓ Biomarker testing results: full laboratory report (not just a notation in the clinical note), including the testing laboratory, assay platform, and result with reference ranges
✓ Prior treatment documentation: regimen names, start/end dates, best response, reason for discontinuation
✓ ECOG or Karnofsky performance status from a clinical note dated within the prior 90 days
✓ NCCN guideline citation: the specific tumor type guideline, version/date, and the page/algorithm step that supports the request
✓ For Medicare Part B oncology (J-code drugs): ICD-10-CM codes for the primary malignancy (C-codes) must be at maximal specificity including laterality and histology modifiers where applicable
✓ For CAR-T: bone marrow biopsy documenting relapsed/refractory status, number of prior lines of therapy with regimens listed, and qualifying institution/infusion center documentation

Checkpoint Inhibitor Prior Authorization

Pembrolizumab (Keytruda), nivolumab (Opdivo), atezolizumab (Tecentriq), durvalumab (Imfinzi), cemiplimab (Libtayo), and ipilimumab (Yervoy) are the most commonly prescribed checkpoint inhibitors. Each has multiple FDA-approved indications across dozens of tumor types, and new approvals continue to expand the label landscape. PA requirements for checkpoint inhibitors have several consistently required elements regardless of payer:

✓ Confirmed diagnosis: pathology-confirmed malignancy with the specific tumor type, histology, and (where relevant) stage
✓ PD-L1 testing: for pembrolizumab monotherapy in most solid tumors, PD-L1 TPS or CPS result from a validated assay (Dako 22C3 for TPS in NSCLC; Dako 22C3 or SP142 depending on tumor type for CPS)
✓ MSI-H/dMMR for tumor-agnostic pembrolizumab indication: MSI/MMR testing result from an FDA-approved assay (PCR-based MSI or IHC-based MMR protein expression)
✓ TMB-H for tumor-agnostic pembrolizumab in solid tumors (KEYNOTE-158): TMB ≥10 mut/Mb by a validated NGS panel (e.g., Foundation Medicine FoundationOne CDx)
✓ Prior therapy for second-line or later indications: documentation of the prior platinum-based regimen (for lung) or prior systemic therapy where applicable
✓ Combination regimen components: if the checkpoint inhibitor is being used in combination (e.g., pembrolizumab + pemetrexed + carboplatin for non-squamous NSCLC), all components of the regimen should be included in the PA request
✓ Specialist involvement: most payers require the PA to originate from or be co-signed by a board-certified oncologist

CAR-T Cell Therapy Prior Authorization

CAR-T therapies — axicabtagene ciloleucel (Yescarta), tisagenlecleucel (Kymriah), lisocabtagene maraleucel (Breyanzi), idecabtagene vicleucel (Abecma), ciltacabtagene autoleucel (Carvykti), and brexucabtagene autoleucel (Tecartus) — represent the most administratively complex oncology prior authorization category. PA timelines for CAR-T are longer, documentation requirements are more extensive, and payers often impose institution-level requirements in addition to patient-level criteria.

Key CAR-T-specific PA elements not required for other oncology drugs:

✓ Treating institution certification: payers require that the infusion center is a certified CAR-T administration site (FACT-accredited or REMS-enrolled, depending on the product)
✓ Relapsed/refractory documentation: stringent documentation of the number of prior lines of therapy, specific regimen names and dates, and response assessment (CR, PR, SD, PD) at the end of each line
✓ Bone marrow or biopsy documentation confirming relapsed/refractory disease
✓ Pre-treatment workup: LVEF (≥50% typically required), organ function (creatinine, bilirubin, LFTs), bridging therapy if applicable
✓ Bridging therapy documentation: many payer criteria require documentation of whether bridging therapy was used between leukapheresis and infusion
✓ Medicare CAR-T coverage: Medicare pays for CAR-T under the hospital outpatient prospective payment system (OPPS) with pass-through reimbursement; prior authorization is handled by MAC contractors; Medicare Advantage plans have separate PA requirements and may impose additional criteria beyond CMS baseline
✓ CAR-T PA denials frequently cite "experimental/investigational" or "failure to meet medical necessity" — always cite the specific FDA approval, NCCN guideline category, and clinical trial data (ZUMA, JULIET, TRANSFORM, etc.) that supports the request

Oncology Drug PA by Payer: Key Differences

While NCCN provides a baseline framework, individual payers apply it differently. Key variations by major payer:

✓ UnitedHealthcare: CDGs generally follow NCCN 1/2A; medical oncology PA submitted via Availity; UHC has implemented a Gold Carding program for oncology practices with high PA approval rates; oncology PA decisions typically within 3 business days
✓ Aetna: CPBs for oncology closely track NCCN with explicit biomarker criteria; Aetna's oncology PA often includes a "step" where the CPB specifies which prior treatments are required — even for second-line therapies that are NCCN 2A, the CPB may require documentation of a specific first-line regimen
✓ Cigna: Coverage Policies for oncology require NCCN 1 or 2A support; Cigna's Oncology Management program employs oncology nurse reviewers and medical directors; Cigna peer-to-peer for oncology can be requested through availity; Cigna tends to apply more aggressive step therapy in hematologic malignancies
✓ BCBS plans: vary by state affiliate; Federal Employee Program (FEP) Blue generally follows NCCN strictly; BCBS commercial plan policies vary and must be reviewed individually
✓ Medicare Part B: MAC contractors (Noridian, Palmetto, NGS, etc.) publish Local Coverage Determinations (LCDs) for specific drugs; LCDs may be more or less restrictive than NCCN depending on the MAC jurisdiction; an LCD denial is not an NCCN denial — they are separate policy instruments
✓ Medicare Advantage: follows CMS requirements with mandatory NCCN alignment for cancer drugs; MA plans cannot impose additional step therapy requirements beyond what CMS allows for cancer treatment

Appealing an Oncology PA Denial

Oncology PA denials are some of the highest-priority appeals in specialty pharmacy because treatment delays directly affect patient outcomes. The appeal framework is the same as other PA denials but with additional leverage points specific to oncology:

✓ Lead with NCCN: cite the specific guideline, version, algorithm step, and category. Most payer policies explicitly commit to covering NCCN 1 and 2A — show the reviewer the exact text
✓ Biomarker precision: if the denial was biomarker-related, provide the full lab report with assay platform, result, and reference range. A notation in a chart note ("PD-L1 positive") is not sufficient; the actual laboratory report is required
✓ Peer-reviewed trial data: cite the pivotal trial that led to FDA approval or NCCN inclusion (KEYNOTE, CheckMate, SOLO, PRIMA, etc.) with the primary endpoint data
✓ Urgency: oncology appeals can and should be filed as expedited when delay would seriously jeopardize health or ability to regain maximum function — this is explicitly applicable to cancer patients where treatment timing is clinically critical
✓ Peer-to-peer: request immediately upon denial; ensure the payer schedules the P2P with a specialty-matched physician (oncologist, not internist); this is often critical for complex biomarker-driven regimens
✓ External review: oncology denials have strong external review outcomes, particularly for NCCN-supported off-label uses; most state IROs and CMS-contracted IREs are required to consider NCCN guidelines as part of the clinical evaluation standard
✓ Medicare Advantage oncology: cite 42 CFR 422.568(b) timelines in all MA appeals; MA plans cannot apply step therapy for cancer chemotherapy agents inconsistent with NCCN guidelines under CMS rules

How RxCheckUp Handles Oncology PA

RxCheckUp generates oncology LMNs with NCCN guideline citations, biomarker-specific criteria matching, and payer-specific clinical policy references pre-populated. For checkpoint inhibitors, the system pulls the current FDA label indication, the applicable NCCN category, and the biomarker threshold for the specific drug-indication combination — reducing the risk of biomarker threshold errors that are responsible for a large fraction of oncology denials.

For multi-drug regimens (e.g., pembrolizumab + pemetrexed + carboplatin), RxCheckUp generates a single cohesive letter covering all components with the appropriate regimen-level NCCN reference rather than treating each drug in isolation. This is particularly important for combination immunotherapy regimens where the evidence base is the combination trial, not the individual components.